UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/646,615	08/22/2003	William J. Hennen	2820-5474.1US	8609
²⁴²⁴⁷ TRASK BRITT	7590 11/17/200	8	EXAMINER	
P.O. BOX 2550) TTY, UT 84110	KIM, TAEYOON		
SALI LAKE C	111,0104110		ART UNIT	PAPER NUMBER
			1651	
			NOTIFICATION DATE	DELIVERY MODE
			11/17/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTOMail@traskbritt.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/646,615	HENNEN, WILLIAM J.		
	ı		
Examiner	Art Unit		

	TAETOON KIIVI	1651	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>09 October 2008</u> FAILS TO PLACE THIS A	PPLICATION IN CONDITION FOR	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperfor Continued Examination (RCE) in compliance with 37 Comperiods:	the same day as filing a Notice of A replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejection	n.
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(1) Extensions of time may be obtained under 37 CFR 1.136(a). The date	f).		
have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
NOTICE OF APPEAL	"		5.11
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
<u>AMENDMENTS</u>			
 The proposed amendment(s) filed after a final rejection, the same of the proposed amendment(s) filed after a final rejection, the same of the proposed amendment(s) filed after a final rejection, the proposed amendment(s) filed after a final rejection in the proposed amendment(s) filed after a final rejection in the proposed amendment(s) filed after a final rejection in the proposed amendment filed after a final rejection in the proposed amendment filed after a filed afte			cause
(b) They raise the issue of new matter (see NOTE below		•	
(c) They are not deemed to place the application in bet appeal; and/or	ter form for appeal by materially rec	ducing or simplifying tl	ne issues for
(d) They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: See Continuation Sheet. (See 37 CFR 1.1	16 and 41.33(a)).		
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Co	mpliant Amendment (I	PTOL-324).
5. 🛛 Applicant's reply has overcome the following rejection(s):	claim rejection under 35 U.S.C.11	2, 1 st para.	
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 			nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		l be entered and an e	xplanation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: <u>1.4-8,11,12,14-16,18,50,53-57 and 59-5</u> Claim(s) withdrawn from consideration:	<u>78</u> .		
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.
11. The request for reconsideration has been considered but See Continuation Sheet.	t does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)		
13.	, , , , , , , , , , , , , , , , , , ,		
	/Leon B Lankford/ Primary Examiner, Art U	nit 1651	
	i fillary Examiner, Art O	1111 1001	

Continuation of 3. NOTE: The proposed amendment discloses a new limitation of nutritional supplement comprising a cardiovascular support component, which raises a new issue to consider.

Continuation of 11. does NOT place the application in condition for allowance because: The response to the previous office action, applicant argued that Ramaekers et al. do not teach transfer factor specific for HSV. Even though Ramaekers do not disclose the transfer factor of the composition being HSV specific, it is well knonw in the art that transfer factor can be generated as specific to pathogens. With regard to the argument based on the additional components present in the composition of Ramaekers, the proposed amendment drawn to a nutritional supplement would encompass lactic acid bacteria, zinc, and essential amino acids, and these ingredient may not be a part of "cardiovascular support component" per se. The transitional phrase of "consist of" is limited to "a cardiovascular support component". Based on the above discussion, the current amendment does not place the application in condition for allowance.

Taeyoon Kim AU-1651